Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etheno-NAD
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
Etheno-NAD (1,N6-ethenoadenine dinucleotide, ε-NAD) is a fluorescent analog of nicotinamide adenine dinucleotide (NAD). It is primarily used as a research tool rather than as a therapeutic drug. Etheno-NAD is intensely fluorescent and serves as a substrate for various NAD-dependent enzymes in biochemical assays. Its fluorescence properties allow sensitive detection and quantification of enzyme activities such as ADP-ribosylation and poly(ADP-ribose) polymerase (PARP) activity in vitro. Etheno-modified nucleotides like etheno-NAD are not approved for clinical use but are valuable in experimental settings to study NAD metabolism, enzyme kinetics, and cellular processes involving NAD-utilizing enzymes[1][3][7].
- Other names
- etheno-NAD1,N6-ethenoadenine dinucleotideε-NAD
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on etheno-NAD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etheno-NAD.